Gilead Sciences to present breakthrough cancer therapy data at medical conferences, showcasing promising results.

From Yahoo Finance: 2025-05-18 15:26:00

Gilead Sciences, Inc. (GILD) is set to present over 20 research abstracts at the 2025 ASCO Annual Meeting and 2025 EHA Congress, showcasing breakthrough cancer therapies for various types of cancers. Key highlights include Phase 3 results showing improved survival rates in patients with triple-negative breast cancer and Phase 1 findings on a new CAR T-cell therapy for aggressive brain cancer. GILD’s Chief Medical Officer, Dietmar Berger, highlighted the company’s commitment to innovation in cancer treatment. Despite its promising pipeline, GILD also impresses investors with strong financial performance, including consistent dividend payouts and a 51% stock surge in 2025.



Read more at Yahoo Finance: Gilead Sciences, Inc. (GILD) and Kite to Present Breakthrough Cancer Therapy Data at 2025 ASCO and EHA